CTOs on the Move

HTG Molecular Diagnostics

www.htgmolecular.com

 
Headquartered in Tucson, Arizona, HTG is focused on advancing precision medicine. The company`s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

HTG Molecular Diagnostics raised $22.5M on 10/03/2019

Similar Companies

Signum Biosciences Inc

Signum Biosciences Inc is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuroVision Imaging

NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease. The company has developed a novel retinal imaging technology, that is incorporated into a number of clinical trials globally.

Pharmagreen Biotech

harmagreen is a company focused on BIOTECH SCIENCES utilizing proprietary technologies and formulations in its state of the art CANNABIS BOTANY CENTER

Ethicon Endo-Surgery

Ethicon Endo-Surgery is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ansun Biopharm

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.